Pharmacy & Therapeutics - November 2008 - (Page 641)

DRUG FORECAST biprole for the treatment of CAP and hospital-acquired pneumonia (HAP) have also been completed but are available only in abstract form. Investigators noted in the trial for HAP that non-inferiority could not be established in the subgroup of patients with ventilator-assisted pneumonia (VAP), because clinical cure rates were significantly lower in the ceftobiprole group of patients than in the comparator group. It is not clear why ceftobiprole underperformed in this group of patients; the use of ceftobiprole for the treatment of VAP warrants further research. With antimicrobial resistance on the rise and the pipeline of active agents against gram-negative pathogens relatively nonexistent, hospitals and clinicians are constantly being challenged to develop new strategies to treat complicated infections while preserving antimicrobials for the future. Although ceftobiprole provides us with another option in our antimicrobial armamentarium, further research of its role in clinical practice is still required. The judicious use of this agent will be imperative, in view of the lack of newer antimicrobial agents (with activity against multidr ug-resistant, gram-negative pathogens) that are expected to be available in the near future. microbial activity of ceftobiprole, a novel anti–methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagn Microbiol Infect Dis 2008;61(1):86–95. Jones RN, Deshpande LM, Mutnick AH, et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002;50:915–932. Pillar CM, Aranza MK, Shah D, et al. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008;61(3):595–602. Murthy B, Schmitt-Hoffman A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008;47:21–33. Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of RO 63-9141, a novel broad-spectrum cephalosporin with activity against methicillinresistant staphylococci. Antimicrob Agents Chemother 2001;45:825–836. Lovering A, Daniel F, Page MG, et al. Mechanism of action of ceftobiprole: Structural bases for anti-MRSA activity (poster 1586). Presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1–4, 2006. Bogdanovich T, Ednie LM, Shapiro S, et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49:4210–4219. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2974–2976. Banerjee R, Gretes M, Basuino L, et al. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2089–2096. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2570–2575. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2576–2580. Roos B, Schmidt-Hoffman A, Schleimer M. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function (Abstract A-23). Presented at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003. 20. Lodise TP, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007;51: 2378–2387. 21. Schmitt-Hoffmann AH. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of Pro-drug BAL5788 (Abstract 902). Presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 1–4, 2004. 22. Andes DR, Craig WA. In vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens (Abstract F-1079). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. 23. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007;13(Suppl 2):25−29. 24. Noel GJ, Straus RS, Amsler K, et al. Treatment of complicated skin and skin structure infections caused by gram-positive bacteria with ceftobiprole: Results of a double-blind, randomized trial. Anti microb Agents Chemother 2008;52:37–44. 25. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and softtissue infections. Clin Infect Dis 2005;41: 1373–1406. 26. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis 2008; 46:647–655. 27. Nicholson SC, Strauss RS, Michiels B, et al. Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with community-acquired pneumonia (poster C-17). Presented at the American Thoracic Society International Conference, Toronto, May 16–21, 2008. 28. Basilea announces positive top-line data from phase III study of ceftobiprole in community-acquired pneumonia requiring hospitalization. Basel: Basilea Pharmaceutica, Ltd.; September 14, 2007. Available at: www.basilea.com. 29. Nicholson SC, Strauss RS, Michiels B, et al. Efficacy of ceftobiprole compared to ceftriaxone +/- linezolid for the treatment of subjects hospitalized with communityacquired pneumonia (poster C-16). Presented at American Thoracic Society Inter national Conference, Toronto, May 16–21, 2008. 30. Basilea announces positive top-line data from phase III study of ceftobiprole in hospital-acquired pneumonia. Basel: Basilea Pharmaceutica, Ltd.; October 9, 2007. Available at: www.basilea.com. 31. Chan P, Bishop A, Kupiec TC, et al. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 2008;65(16):1545–1551. I 9. 10. 11. 12. 13. 14. REFERENCES 1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis 2007;13(12):1840–1846. 2. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763–1771. 3. Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985;3: 397–403. 4. Livermore DM. Can beta-lactams be reengineered to beat MRSA? Clin Microbiol Infect 2006;12(Suppl 2):11–6. 5. Adis R&D profile. Ceftobiprole medocaril. Drugs RD 2006;7(5):305–311. 6. Walkty A, DeCorby M, Nichol K, et al. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN–ICU Study. J Antimicrob Chemother 2008;62(1):206–208. 7. Jones ME. In vitro profile of a new betalactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007;13(Suppl 2):17−24. 8. Fritsche TR, Sader HS, Jones RN. Anti15. 16. 17. 18. 19. Vol. 33 No. 11 • November 2008 • P&T® 641 http://www.basilea.com http://www.basilea.com

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - November 2008

Pharmacy & Therapeutics - November 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/New Medical Devices Drug Forecast Heparin-Induced Thrombocytopenia Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched From Fixed-Dose to Free-Combination Antihypertensive Therapy European Society for Medical Oncology and Association for the Study of Bone and Mineral Research Pharmaceutical Approval Update

Pharmacy & Therapeutics - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.